Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

NCT05381662 is registered in ClinicalTrials.gov with Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd as lead sponsor.

NCT NCT05381662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05381662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment
Lead sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 2, 2018
Completion date
December 1, 2025
Enrollment
10 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia in remission